catechin and Eye Burns

catechin has been researched along with Eye Burns in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Castro-Muñozledo, F; González-Robles, A; Gulias-Cañizo, R; Lagunes-Guillén, A; Sánchez-Guzmán, E1
Lu, M; Wu, LQ1
Chang, CY; Chen, KH; Chen, ZY; Lin, FH; Liu, GS; Miyagawa, T; Tseng, CL; Wang, MC1

Other Studies

3 other study(ies) available for catechin and Eye Burns

ArticleYear
(-)-Epigallocatechin-3-gallate, reduces corneal damage secondary from experimental grade II alkali burns in mice.
    Burns : journal of the International Society for Burn Injuries, 2019, Volume: 45, Issue:2

    Topics: Alkalies; Animals; Antioxidants; Burns, Chemical; Catechin; Caustics; Cell Cycle; Cell Differentiation; Cell Line; Cell Proliferation; Cornea; Corneal Neovascularization; Corneal Opacity; Epithelium, Corneal; Eye Burns; Mice; Rabbits; Sodium Hydroxide; Wound Healing

2019
[Efficacy of epigallocatechin gallate in treatment of alkali burn injury of murine cornea].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:1

    Topics: Alkalies; Animals; Burns, Chemical; Catechin; Cornea; Corneal Neovascularization; Disease Models, Animal; Eye Burns; Inflammation; Mice; Mice, Inbred C57BL; Neutrophils; RNA, Messenger; Vascular Endothelial Growth Factor A

2015
Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
    International journal of nanomedicine, 2017, Volume: 12

    Topics: Angiogenesis Inhibitors; Animals; Burns, Chemical; Catechin; Cell Survival; Corneal Neovascularization; Disease Models, Animal; Eye Burns; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Integrin alphaVbeta3; Mice, Inbred C57BL; Molecular Targeted Therapy; Nanoparticles; Oligopeptides; Ophthalmic Solutions

2017